Martin B. Gill, PhD
Director, Head of In Vitro Pharmacology at Neuropore Therapies, Inc.
Location: San Diego, California, United States
Martin Gill, PhD, joined the Neuropore Therapies team in 2016, where he manages the in vitro discovery efforts to identify, validate, and optimize novel small molecule therapeutic assets for inflammation- and autophagy-based targets. Prior to his time at Neuropore, he served in the Genetically-Defined Disease division at Bristol-Myers Squibb where he managed a senior scientific team focused on in vitro/in vivo assay development to support portfolio program progression. In addition, was biology co-chair for internal small molecule and antisense programs and managed the biological evaluation of in-licensing asset opportunities. Dr. Gill was also previously a member of the Neuroscience Discovery team at Eli Lilly and Company supporting target identification/validation and lead optimization efforts. He received his doctorate in neuroscience from the University of Texas-Medical Branch investigating neurodegenerative apoptotic and necroptotic signaling. He conducted post-doctoral work at Northwestern University, Feinberg School of Medicine, in glutamate receptor biogenesis and electrophysiology, in addition to identifying and evaluating novel, marine-based pharmacophores that could modulate neuronal function.